+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tyrosine Kinase Inhibitors Market - Global Forecast 2026-2032- Product Image
Tyrosine Kinase Inhibitors Market - Global Forecast 2026-2032- Product Image
New

Tyrosine Kinase Inhibitors Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5715482
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Tyrosine Kinase Inhibitors Market is evolving in response to new scientific, clinical, and commercial imperatives, demanding focused strategies from biopharmaceutical leaders and stakeholders committed to driving innovation and value across oncology therapeutics.

Market Snapshot: Tyrosine Kinase Inhibitors Market Growth

The Tyrosine Kinase Inhibitors Market grew from USD 68.21 billion in 2025 to USD 73.36 billion in 2026. It is projected to expand at a CAGR of 7.30%, reaching USD 111.75 billion by 2032.

Scope & Segmentation

This report delivers a comprehensive analysis of the heterogeneous landscape of tyrosine kinase inhibitors, focusing on pivotal segmentations and regional perspectives. Market evaluation spans the following key areas:

  • Indications: Assessment covers major oncologic applications such as Breast Cancer, Chronic Myeloid Leukemia, Non-Small Cell Lung Cancer, and Renal Cell Carcinoma, each requiring tailored clinical and commercial strategies.
  • Molecular Targets: Strategies are analyzed by focus areas including ALK, BCR-ABL, EGFR, and VEGFR, considering sequential development and resistance pathways.
  • Generation: Differentiation among first, second, and third-generation agents, highlighting their roles in addressing clinical endpoints and overcoming resistance mutations.
  • Route of Administration: Distinction between intravenous and oral formulations, with consideration for patient adherence and site-of-care economics.
  • Distribution Channels: Examination of hospital versus retail pharmacy distribution, focusing on how access and reimbursement paths impact diverse therapy types.
  • Regions: In-depth regional analysis spanning the Americas, EMEA, and Asia-Pacific, addressing variation in regulatory, payer, diagnostics, and manufacturing infrastructures.
  • Technologies: Integrated review of enabling technologies, such as next-generation sequencing, liquid biopsy, real-world evidence tools, and companion diagnostics that accelerate targeted development.

Key Takeaways

  • Scientific innovation and translational research have redefined target selection, fostering more precise and resistance-aware molecule discovery and clinical validation.
  • Market leaders must balance value-based evidence, patient-centric formulation choices, and strategic access planning to achieve sustainable commercialization.
  • Successful development programs increasingly integrate real-world data and rapid-cycle, biomarker-driven trial designs for faster regulatory and payer alignment.
  • Regional variation in regulatory and commercial frameworks necessitates tailored launch models, flexible pricing, and diagnostic alignment for optimal reach and adoption.
  • Stakeholder strategies now prioritize not only efficacy but also tolerability, real-world adherence, and integration into chronic care pathways to address evolving clinical expectations.

Tariff Impact on Supply Chain and Commercial Planning

Recent U.S. tariff changes have intensified manufacturing and supply chain challenges for tyrosine kinase inhibitors. Increased production costs for both active ingredients and packaging components have led to adjusted list pricing strategies and require supply chain resilience. Pharmaceutical manufacturers respond by diversifying their supplier bases, securing long-term contracts with preferred vendors, and expanding regional inventories. These shifts demand adaptive pricing, outcomes-based agreements, and robust governance to balance affordability with uninterrupted patient access.

Methodology & Data Sources

The findings presented are based on a triangulated research process integrating expert interviews with clinicians, molecular pathologists, payers, and commercial leaders, along with secondary literature, regulatory guidelines, and clinical trial registries. Scenario and sensitivity analyses ensure robust, actionable insights with transparent documentation of data sources and assumptions.

Why This Report Matters

  • Provides actionable, evidence-based frameworks to guide strategic decision-making on product development, market access, and geographic expansion in oncology therapeutics.
  • Empowers leaders to anticipate regulatory, manufacturing, and payer-driven shifts, supporting proactive lifecycle planning and resilience across commercial and operational functions.

Conclusion

Integrating diagnostic-driven development and resilient supply strategies is key to achieving clinical and commercial differentiation in the tyrosine kinase inhibitors landscape. Decision-makers leveraging this analysis can align scientific advancement with effective market execution, sustaining value in a rapidly evolving oncology market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Tyrosine Kinase Inhibitors Market, by Indication
8.1. Breast Cancer
8.2. Chronic Myeloid Leukemia
8.2.1. First Line
8.2.2. Second Line
8.2.3. Third Line
8.3. Non Small Cell Lung Cancer
8.3.1. First Line
8.3.2. Second Line
8.3.3. Third Line
8.4. Renal Cell Carcinoma
9. Tyrosine Kinase Inhibitors Market, by Target
9.1. Alk
9.2. Bcr-Abl
9.2.1. First Generation
9.2.2. Second Generation
9.2.3. Third Generation
9.3. EGFR
9.3.1. First Generation
9.3.2. Second Generation
9.3.3. Third Generation
9.4. Vegfr
10. Tyrosine Kinase Inhibitors Market, by Generation
10.1. First Generation
10.2. Second Generation
10.3. Third Generation
11. Tyrosine Kinase Inhibitors Market, by Route Of Administration
11.1. Intravenous
11.2. Oral
12. Tyrosine Kinase Inhibitors Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Retail Pharmacies
13. Tyrosine Kinase Inhibitors Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Tyrosine Kinase Inhibitors Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Tyrosine Kinase Inhibitors Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Tyrosine Kinase Inhibitors Market
17. China Tyrosine Kinase Inhibitors Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Astellas Pharma Inc.
18.7. AstraZeneca plc
18.8. Bayer AG
18.9. Blueprint Medicines Corporation
18.10. Boehringer Ingelheim International GmbH
18.11. Bristol-Myers Squibb Company
18.12. Eli Lilly and Company
18.13. Exelixis, Inc.
18.14. GlaxoSmithKline plc
18.15. Incyte Corporation
18.16. Merck & Co., Inc.
18.17. Novartis AG
18.18. Pfizer Inc.
18.19. Rigel Pharmaceuticals, Inc.
18.20. Roche Holding AG
18.21. Sanofi S.A.
18.22. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 136. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 137. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 138. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 139. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 140. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 156. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 157. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 158. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 159. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 160. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 161. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 176. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 177. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 178. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 179. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 180. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 181. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 182. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 186. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 187. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 188. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 189. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 190. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 191. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 192. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 207. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 208. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 209. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 210. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 211. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 212. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 216. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 217. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 218. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 219. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 220. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 221. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 222. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 225. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 226. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 227. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 228. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 229. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 230. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 231. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 232. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 234. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 247. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 248. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 249. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
TABLE 250. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
TABLE 251. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
TABLE 252. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
TABLE 253. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Tyrosine Kinase Inhibitors market report include:
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 73.36 Billion
Forecasted Market Value ( USD ) by 2032 $ 111.75 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Tyrosine Kinase Inhibitors Market - Global Strategic Business Report - Product Image

Tyrosine Kinase Inhibitors Market - Global Strategic Business Report

  • Report
  • 290 Pages
  • Global
From
Tyrosine Kinase Inhibitors Market Report 2025 - Product Image

Tyrosine Kinase Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Tyrosine Kinase Inhibitor (TKI) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

Tyrosine Kinase Inhibitor (TKI) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 98 Pages
  • Global
From
Bruton's Tyrosine Kinase Inhibitor Pipeline Analysis Report 2025 - Product Image

Bruton's Tyrosine Kinase Inhibitor Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Bruton Tyrosine Kinase (BTK) Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

Bruton Tyrosine Kinase (BTK) Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 85 Pages
  • Global
From

About the Tyrosine Market

Tyrosine Kinase Inhibitors (TKIs) are a class of pharmaceuticals that target tyrosine kinase enzymes, which are involved in the activation of signal transduction pathways that ultimately lead to cell division and proliferation. The dysregulation of tyrosine kinases is a common feature in the pathogenesis of various types of cancer, leading to unchecked cell growth and tumor development. TKIs are therefore an important class of anticancer agents that have reshaped the drug discovery landscape, especially in the treatment of cancers with identifiable molecular targets. In the realm of drug discovery, the market for TKIs has matured with the approval of numerous agents that cover a wide spectrum of targets. Research and innovation focus on improving the efficacy and reducing the side effects, which can include kinome non-selectivity leading to off-target effects. Moreover, the emergence of resistance to first-generation TKIs has spurred the development of second- and third-generation inhibitors that aim to overcome resistance by binding to the kinase domain of mutant enzymes. Several companies are prominent players in the TKI market, frequently associated with pioneering research and the introduction of novel therapeutics. Key names include Novartis, Pfizer, Roche, AstraZeneca, and Bristol Myers Squibb. These companies not only invest heavily in research and development of TKIs but also in the strategic acquisition of smaller biotech firms, partnerships, and collaborations to expand their portfolios and address the diverse needs of patients with cancer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.